Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238492 | 0.97 | TLR8 (0.89) | TLR8TLR7 | |
| Motolimod SCHEMBL29353690 | 0.90 | TLR8 (1.00) | TLR8TLR7 | |
| Motolimod SCHEMBL254984 | 0.90 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL1803349 | 0.89 | TLR8 (0.98) | TLR8TLR7 | |
| SCHEMBL26080080 | 0.88 | TLR8 (0.95) | TLR8TLR7 | |
| SCHEMBL1801525 | 0.87 | TLR8 (0.93) | TLR8TLR7 | |
| SCHEMBL18772046 | 0.87 | TLR8 (0.93) | TLR8TLR7 | |
| SCHEMBL1238499 | 0.86 | TLR8 (0.92) | TLR8TLR7 | |
| SCHEMBL18771808 | 0.86 | TLR8 (0.70) | TLR8TLR7 | |
| SCHEMBL1800351 | 0.86 | TLR8 (0.79) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| EP-3159337-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3159337-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2467380-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2467380-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9242964-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8524702-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524702-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524702-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2467380-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011022509-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011022509-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | TLR8 1/4885TLR7 3/4885 |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | TLR8 1/4885TLR7 3/4885 |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR8 3/4885TLR7 2/4885 |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR7 | TLR8 1/4885TLR7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.